The effect of hyperglycemia on the values of antioxidative parameters in type 2 diabetic patients with cardiovascular complications

Jugoslovenska Medicinska Biohemija

Volumn 25, Issue 2, 2006, Pages 173-179

  Čolak, Emina ^a,b   Majkić Singh, Nada ^a,b   Stanković, Sanja ^a,b   Dordević, Predrag B ^a,c   Dimitrijevic Sreckovic, Vesna ^a,c   Lalic, Katarina ^a,c   Lalić, Nebojša ^a,c  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Institut za Medicinsku Biohemiju   (Macedonia)

^c Inst za Ginekologiju i Akuserstvo   (Yugoslavia)

Author keywords

Antioxidative defense; Cardiovascular complications; Oxidative stress; Type 2 diabetic patients

Indexed keywords

ANTIOXIDANT; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; SUPEROXIDE DISMUTASE;

ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; REVIEW; SPECTROPHOTOMETRY;

EID: 33646785085     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMB0602173C     Document Type: Review

References (41)

1. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovascular Diabetology 2002; 1: 1.
2. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage. Nature 2000; 404: 787-90.
3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1998; 318: 1315-21.
4. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995; 270: 10828-32.
5. 5: Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in uiuo. Proc Natl Acad Sci USA 1993; 90: 6434-38.
6. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-478.
7. Touyz RM. Reactive oxygen species, vascular oxidative stress and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-52.
8. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patients? Atherosclerosis 1993; 102: 63-7.
9. Schmidt AM, Hori O, Brett J, Van SD, Wantier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Atheroscler Thromb 1994; 14: 1521-8.
10. Schmidt AM, Hori O, Chen JX, U JF, Zhang J, Cao R et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
11. Wantier JL, Zoukourian C, Chappey O, Wantier MP, Guillausseau PJ, Cao R, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
12. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 1990; 87: 9010-14.
13. Vlassara H, Brownlee M, Monogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1998; 240: 1546-8.
14. Kirstein M, Aston C, Hints R, Vlassara H. Receptor-specific induction of insulin-like growth factor 1 in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90: 439-46.
15. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical biologic and clinical implications for diabetes and aging. Lab Invest 1994; 70: 138-51.
16. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, Kuning GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hyperglycemic. Diabetes 1994; 43: 1122-9.
17. Koya D, Haneda M, Nakagawa H, Isshiki K, Soto H, Maeda S et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic DB/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-47
18. Park JY, Takohara N, Gabriele A, Chou E, Naruse K, Suzuma K et al. Induction of endothelin expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49: 1239-48.
19. Nabel E, Shum L, Pompili V, Yang ZY, San H, Liptay S et al. Direct transfer of transforming growth factor b1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 1993; 90: 10759-63.
20. Wolf SP. Diabetes mellitus and free radicals. Free radical transition metals and oxidative stress in the aethiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-52.
21. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new prospective on an old paradigm. Diabetes 1999; 48: 1-9.
22. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia 1995; 38: 201-10.
23. Dominguez C, Ruiz E, Gussinye M, Carracosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998; 21: 1736-42.
24. Chen MS, Hutchinson ML, Pecoraro RE, Lee WY, Labbe RF. Hyperglycemia-induced intracellular depletion of ascorbic acid in human mononuclear leukocytes. Diabetes 1983; 32: 1078-81.
25. Yue DK, McLennan S, Fisher E, Hefferman S, Capogreco C, Ross GR et al. Ascorbic acid metabolism and polyol pathway in diabetes. Diabetes 1989; 38: 257-61.
26. Goldstein S, Michel C, Boors A, Saran M, Czapsky G. A critical re-evaluation of some assay methods for superoxide dismutase activity. Free Radical Biol Med 1988; 4: 295-303.
27. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterisation of glutathione peroxidase. J Lab Clin Med 1967; 70: 158-63.
28. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993; 84: 407-12.
29. rd ed. New York: Academic Press 1974, Vol 3, p. 258-65.
30. Čolak E, Majkić-Singh N, Stanković S, Srećković-Dimitrijević V, crossed D signedorcrossed d signedević PB, Lalić K et al. Parameters of antioxidative defense in type 2 diabetic patients with cardiovascular complications. Ann Med 2005; 37: 613-20.
31. Dimitrijević-Srećković SV, crossed D signedorcrossed d signedević PB, Popović SS, Gostiljac D, Canović F, Srećković MB et al. Metabolic syndrome and antioxidative activity in early glycoregulation disorders. Diabetologia 2004; 47 (Suppl 1): A143 (Abstract book of the 40th Annual Meeting of the EASD, Munich, Germany, 5-9 September 2004).
32. Oda A, Bnnai C, Yamaoka T, Katori T, Matsushima T, Yamashita K. Inactivation of Cu,Zn-SOD by in vitro glycosylation and in erythrocytes of diabetic patients. Horn metab res 1994; 26 (1): 1-4.
33. Kesavulu MM, Giri R, Kameswara RB, Apparo Ch. Lipid peroxidation and antioxidant levels in type 2 diabetics with microvascular complications. Diabetes & Metabolism 2000; 25 (5): 387-95.
34. Siemianowich K, Gminski J, Francuz T, Wujcik A, Posielezna B. Activity of antioxidant enzymes in children from families at high risk of premature coronary heart disease. Scand J Clin Lab Invest 2003; 63 (2): 151-8.
35. Valabhji J, McColl AJ, Richmond W, Schacher M, Rubens MB, Elkeles RS. Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care 2001; 24: 1608-13.
36. Lapenna D, De Gioia S, Ciofani G, Mezzetti A, Ucchino S, Calafiore AM et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 1998; 97: 1930-34.
37. Kinter M, Roberts RJ. Glutathione consumption and glutathione peroxidase inactivation in fibroblast cell lines by 4-hydroxy-2-nonenal. Free Radic Biol Med 1996; 21: 457-62.
38. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349 (17): 1605-13.
39. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 2002; 106(9): 1154-8.
40. Raes M, Michiels C, Remacle J. Comparative study of the enzymatic defense system against oxygen-derived free radicals: the key role of glutathione peroxidase. Free Radic Biol Med 1987; 3: 3-7.
41. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaques contain both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995; 15: 1616-24.